Antoni Chan MD (Prof) synovialjoints
1 year 1 month ago
In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR 1.20), depression (OR 1.22). D2T group had higher CRP (55.7 mg/L), BMI (31.1), and more EAMs (IBD, psoriasis, uveitis). Female predominance (56.9%)Abstract https://t.co/EHCt5wq4ot
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 1 month ago
#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal dose. Particulary important in those with CKD Stage =>3 as considered high risk of toxicity. Next steps: wider availability & cost-effectiveness analysis @RheumNow https://t.co/WoVFolrmPA
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 1 month ago
#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved? Registry in Sweden showed factors associated with damage/mortality:
- Lower income & education,
- No partner
- On sick leave/disability benefits
@RheumNow https://t.co/hgEfJzoqNg
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 1 month ago
#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RCT, compared with PBO+SOC, Dapirolizumab+SOC resulted in higher rates of achievement and time in LLDAS and DORIS. LLDAS plateud after WK28 in PBO+SOC @RheumNow https://t.co/3Zd3jjx984
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 1 month ago
#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib were maintained through to Week 104. Those who switched from PBO at WK48 to UPA + ELSU also improved. No VTE or MACE. Is add-on ELSU really needed? @RheumNow https://t.co/x8NbAtsHh0
Dr. John Cush RheumNow
1 year 1 month ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow
1 year 1 month ago
Live Daily Eular 2025 Recap Day 1 https://t.co/dLV83VcGuC
David Liew drdavidliew
1 year 1 month ago
Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI
Janet Pope Janetbirdope
1 year 1 month ago
#neuromodulation in #rheumatoid #arthritis
What is it?
👇
Autonomic & immune system interaction
Who seeks this Rx?
desperate pts w pain
No Rx left
Interested in technology
#EULAR2025 @RheumNow @eular_org
#D2T #RA https://t.co/XWWFiUK6Em
Janet Pope Janetbirdope
1 year 1 month ago
#vagal & #splenic #nerves most studied
In #immune #system interaction
#PNS can detect #inflammation
use in #D2T #RA w active disease ?
Key factors in #neurostimulation - many
#EULAR2025 @RheumNow @eular_org
#D2T in #RA session https://t.co/tCgpGtI5z2
Aurelie Najm AurelieRheumo
1 year 1 month ago
The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases?
A thread 🧵👇🏼
@RheumNow #EULAR2025 https://t.co/KLZN9MvcFy
David Liew drdavidliew
1 year 1 month ago
Interesting debate today #EULAR2025 about medical cannabis - where relative harms have come up.
Would you rather be addicted to prescription opioids or recreational cannabis?
(not going to argue about cannabis addiction - let’s say social impact is equal)
@RheumNow
Janet Pope Janetbirdope
1 year 1 month ago
#Vagal #nerve #stimulation
Hand held device
#BDMARD failure
Plausible - improved pro inflammatory cytokines
wears off benefit if stopped
Attenuates in ~half over yrs
Open label uncontrolled
@RheumNow @eular_org #EULAR2025
Session D2T-RA https://t.co/98K5gwasHv
Janet Pope Janetbirdope
1 year 1 month ago
#RCT of #vagus #nerve #stimulation in #bDMARD-IR #RA Pts
RESSET RCT
+RA #RCT w #VNS
But low response with stat significance
ACR20 1/4 sham vs 1/3 VNS
Would add on to new SoC? 🤔
#EULAR2025 @RheumNow #eular_org
#D2T- RA-session https://t.co/tR1pLPBr74

